We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.51B
AUM Growth
+$203K
Cap. Flow
-$184M
Cap. Flow %
-4.08%
Top 10 Hldgs %
82.68%
Holding
115
New
24
Increased
20
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$15.8M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
3
MET icon
MetLife
MET
+$10.7M
4
TSRO
TESARO, Inc.
TSRO
+$8.14M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.5M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$41.4M
2
BLUE
bluebird bio
BLUE
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.9M
4
CELG
Celgene Corp
CELG
+$12M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.24M

Sector Composition

Rank Sector Weight
1 Consumer Staples 44.81%
2 Healthcare 28.52%
3 Consumer Discretionary 10.77%
4 Financials 0.73%
5 Industrials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OIH icon
26
CALL
VanEck Oil Services ETF
OIH
$1.97B
$15.4M 0.34%
+25,000
New +$16.3M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$38.3B
$15.4M 0.34%
300,000
-200,000
-40% -$9.24M
NBIX icon
28
Neurocrine Biosciences
NBIX
$18.2B
$14.1M 0.31%
325,000
+175,000
+117% +$7.5M
FOLD
29
DELISTED
Amicus Therapeutics
FOLD
$13.5M 0.3%
1,900,000
+150,000
+9% +$948K
ONC
30
BeOne Medicines Ltd
ONC
$33.9B
$13.3M 0.3%
363,286
+63,286
+21% +$2.31M
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$12.4M 0.28%
175,000
+25,000
+17% +$1.46M
ZTO icon
32
ZTO Express
ZTO
$18.2B
$12.4M 0.28%
950,000
-50,000
-5% -$647K
IRWD icon
33
Ironwood Pharmaceuticals
IRWD
$586M
$12.2M 0.27%
855,954
+238,800
+39% +$3.26M
ALXN
34
DELISTED
Alexion Pharmaceuticals
ALXN
$12.1M 0.27%
100,000
-100,000
-50% -$12.9M
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.8M 0.26%
800,000
+300,000
+60% +$4.86M
NKTR icon
36
CALL
Nektar Therapeutics
NKTR
$2.39B
$11.7M 0.26%
33,333
– –
VRTX icon
37
CALL
Vertex Pharmaceuticals
VRTX
$123B
$10.9M 0.24%
100,000
-100,000
-50% -$8.8M
MET icon
38
MetLife
MET
$62.4B
$10.6M 0.23%
+224,400
New +$10.7M
ATRA icon
39
Atara Biotherapeutics
ATRA
$72.6M
$10.3M 0.23%
20,000
– –
TSRO
40
CALL
DELISTED
TESARO, Inc.
TSRO
$10.2M 0.23%
+66,400
New +$10.8M
KITE
41
DELISTED
Kite Pharma, Inc.
KITE
$10.2M 0.23%
130,000
-120,000
-48% -$7.42M
IONS icon
42
Ionis Pharmaceuticals
IONS
$8.93B
$10.1M 0.22%
+250,000
New +$11.2M
RDUS
43
DELISTED
Radius Health, Inc.
RDUS
$9.66M 0.21%
250,000
+150,000
+150% +$6.29M
AVXS
44
DELISTED
AveXis, Inc. Common Stock
AVXS
$9.12M 0.2%
120,000
-30,000
-20% -$1.86M
SRPT icon
45
CALL
Sarepta Therapeutics
SRPT
$1.64B
$8.88M 0.2%
300,000
-300,000
-50% -$9.28M
AGEN
46
Agenus
AGEN
$276M
$8.29M 0.18%
112,090
+10,190
+10% +$807K
RXDX
47
DELISTED
Ignyta, Inc.
RXDX
$8.06M 0.18%
937,000
+87,000
+10% +$636K
TSRO
48
DELISTED
TESARO, Inc.
TSRO
$7.69M 0.17%
+50,000
New +$8.14M
ELF icon
49
e.l.f. Beauty
ELF
$4.77B
$7.2M 0.16%
250,000
+100,000
+67% +$2.7M
MCRB icon
50
Seres Therapeutics
MCRB
$45M
$6.76M 0.15%
30,000
-5,000
-14% -$1.01M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2017 Portfolio in Review

As of Q1 2017, Artal Group held 115 positions worth $4.51B, up 0% from $4.5B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $184M in Q1 2017, closing 20 positions and reducing 23 holdings. Its most notable exit was Celgene Corp, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 45% of assets, down from 47% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Ionis Pharmaceuticals worth $10.1M.

  • Artal Group's largest Q1 2017 buy was Ionis Pharmaceuticals: 250,000 shares worth $10.1M.
  • Artal Group added most to Acceleron Pharma in Q1 2017, an estimated $15.8M increase.
  • Artal Group's biggest Q1 2017 reduction was Incyte, cutting an estimated $41.4M.
  • Artal Group fully exited Celgene Corp in Q1 2017, selling an estimated $12M.
  • Artal Group's ten largest holdings make up 83% of its $4.51B portfolio in Q1 2017.
  • Artal Group opened 24 new positions and closed 20 in Q1 2017.
  • Artal Group's portfolio value rose 0% quarter-over-quarter to $4.51B.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.